Update on antiphospholipid syndrome.
This review addresses new clinical issues (revealed at the 2006 Sydney update of the 1999 Sapporo Classification criteria; cardiac, renal, and multiple sclerosis-like disease; catastrophic syndrome), mechanisms of action of antiphospholipid antibody (very likely complement mediated), current therapies (moderate dose warfarin recommended for prophylaxis, aspirin not recommended for primary prophylaxis), and potential new therapies.